Anticoagulation in COVID-19: DDI Perspective

Sajad Khiali, PharmD1, and Taher Entezari-Maleki, PharmD, PhD1,2,

To The Editors

The novel 2019 coronavirus disease (COVID-19) creates a hypercoagulable state in which thrombotic microangiopathy, and a local disseminated intravascular coagulation (DIC) tends to be the principle cause of death. The COVID-19 hyper-inflammatory state, and inflammatory cytokine releasing, mainly IL-6, is associated with the down-regulation of drug-metabolizing enzymes and transporters activity. During the 1980 influenza epidemic, a clinically significant inflammation-induced loss of CYP1A2 activity led to theophylline toxicity in children.1-4 Notably, drug-drug interactions (DDIs) described here are mainly based on proposed mechanisms of CYP and transporter inhibitory/induction properties.

Considering the key role of the inflammation in the pathogenesis of COVID-19, several immunomodulatory agents are being investigated. TNF-α, IL-1, and IL-6 blocker agents decrease the effects of anticoagulants due to cytochrome P450 enzymes induction. Among them, DDIs of IL-6 inhibitors have attracted the greatest interest. The American Society of Hematology recommended that apixaban and rivaroxaban should not be used with sarilumab and tocilizumab. Moreover, interferon-induced suppression effects on hepatic CYP450 enzymes and consequent drug interactions should be also considered. For example, warfarin dose reduction may be needed. Furthermore, Dexamethasone an inducer of P-glycoprotein in pre-clinical models, and a moderate inducer of CYP3A4. Consequently, its DDIs with anticoagulants should be considered. In the coadministration of warfarin with methylprednisolone, a decreasing dose of warfarin may be required.

Protease inhibitors such as ritonavir/lopinavir and atazanavir have been considered for off-label use in the treatment of COVID-19. These active substances are strong inhibitors of both CYP3A4 and P-glycoprotein and therefore may increase plasma concentrations of factor Xa (FXa) inhibitors to a clinically relevant degree, leading to an increased bleeding risk. Rivaroxaban should be avoided in this treatment scenario, while dose adjustment of warfarin edoxaban, apixaban, and betrixaban may be considered based on the current labeling.

Anti-hepatitis C virus nucleoside analogs including ribavirin, sofosbuvir, and daclatasvir are being investigated for the COVID-19 management. Among them, ribavirin may reduce the anticoagulant effect of warfarin through decreasing warfarin absorption. There is no predicted DDI between daclatasvir and warfarin; however, daclatasvir is a P-glycoprotein inhibitor, and predicted to decrease the metabolism of FXa inhibitors and dabigatran.

Azithromycin could increase the serum concentrations of dabigatran, betrixaban, and edoxaban through P-glycoprotein/ABCB1 inhibition, and the serum concentration of warfarin through unknown mechanisms. Furthermore, among antiparasitic agents, nitazoxanide with probable effects in COVID-19 could increase the warfarin level through protein binding competition (Table 1).

To date, no major DDI has been identified between the COVID-19 investigational agents and parenteral anticoagulants including heparin, low molecular weight heparin, fondaparinux, desirudin, danaparoid, bivalirudin, and argatroban due to their non-CYP-mediated metabolism. Besides, no major DDI has been recognized between other agents including remdesivir, favipiravir, sofosbuvir, chloroquine/hydroxychloroquine, pirfenidone, losartan, fingolimod, bevacizumab, and eculizumab with oral anticoagulants.5-10

Taken together, based on current evidence, parenteral anticoagulants have lower DDIs than oral anticoagulants. Besides, considering metabolism pathways of oral anticoagulants, edoxaban, betrixaban, and dabigatran are less likely to interact with COVID-19 drugs. Finally, hospitalized patients with COVID-19 should be monitored regarding anticoagulation using clinical and laboratory criteria and potential DDIs.

ORCID iD
Sajad Khiali https://orcid.org/0000-0002-2476-4430

1 Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
2 Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Corresponding Author:
Taher Entezari-Maleki, PharmD, PhD, Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Emails: tentezari@gmail.com; entezarim@tbzmed.ac.ir
| Oral anticoagulant agents | Metabolism pathway | Inhibitors of IL-1, IL-6, and TNF-α | Ribavirin | Azithromycin | Lopinavir/ritonavir | Atazanavir | Dadasvair |
|--------------------------|--------------------|-----------------------------------|----------|--------------|---------------------|------------|
| Warfarin                 | CYP2C9 (major), CYP1A2,3A4,2C19 | Restoring or normalizing CYP450 enzymes. Increasing dose may be needed | Possibly decreasing absorption Increasing dose may be needed | Unknown mechanism Decreasing dose may be needed | CYP2C9 inducer CYP3A inhibitor Increasing dose may be needed Adjust dose based on INR. | CYP3A inhibitor Decreasing dose may be needed Adjust dose based on INR. | No interaction expected |
| Rivaroxaban              | CYP3A4 (major), 2J2 BCRP/ABCG2 P-gp/ABCB1 | Restoring or normalizing CYP450 enzyme levels. | No interaction expected | P-gp/ABCBI inhibitor No a priori dose modification is recommended | CYP3A, P-gp /ABCBI inhibitor Do not coadminister | CYP3A, P-gp/ABCBI, and BCRP/ABCG2 inhibitor Do not coadminister. | P-gp/ABCB1 inhibitor. Monitoring is suggested |
| Apixaban                 | CYP3A4 (major), CYP1A2,2C19,2C8,2C9, BCRP/ABCG2P-gp/ABCB1 | Restoring or normalizing CYP450 enzyme levels | No interaction expected | P-gp/ABCBI inhibitor No a priori dose modification is recommended | CYP3A, p-gp /ABCBI inhibitor Administer at 50% of dose (do not administer if initial dose is 2.5 mg twice daily) | CYP3A, P-gp/ABCBI, and BCRP/ABCG2 inhibitor Do not coadminister. | P-gp/ABCBI inhibitor. Monitoring is suggested |
| Edoxaban                 | P-gp/ABCB1 | No interaction expected | No interaction expected | P-gp/ABCBI inhibitor VTE: Limit dose to 30 mg daily Nonvalvular AF: No dose suggested | P-gp/ABCBI inhibitor Reduce dose reduction from 60 mg to 30 mg | P-gp/ABCBI inhibitor Reduce dose reduction from 60 mg to 30 mg | P-gp/ABCBI inhibitor. Monitoring is suggested |
| Betrixaban               | P-gp/ABCB1 | No interaction expected | No interaction expected | P-gp/ABCBI inhibitor Decrease dose to 80 mg once followed by 40 mg daily | P-gp/ABCBI inhibitor Decrease to 80 mg once followed by 40 mg daily | P-gp/ABCBI inhibitor No dose adjustment recommended | P-gp/ABCBI inhibitor. Monitoring is suggested |
| Dabigatran               | P-gp/ABCB1 | No interaction expected | No interaction expected | P-gp/ABCBI inhibitor No dose adjustment recommended | P-gp /ABCBI inhibitor No dose adjustment recommended | P-gp/ABCBI inhibitor No dose adjustment recommended | P-gp/ABCBI inhibitor. Monitoring is suggested |

*S-warfarin (more potent) is metabolized by CYP2C9; whereas, R-warfarin is primarily metabolized by CYP1A2 and CYP3A4. #IL-1 inhibitor is anakinra. IL-6 inhibitors include tocilizumab, sarilimumab, and siltuximab. TNF-α inhibitors include etanercept, infliximab, rituximab,adalimumab, and golimumab. Among them, drug interactions of IL-6 inhibitors have attracted the greatest interest. € Considering ribavirin long half-life, any potential for interactions may persist for up to 2 months after cessation of ribavirin therapy. †These recommendations are based on the U.S. package insert. The Canadian package insert considers the combination of these agents to be contraindicated. ‡The European product label recommended dose reduction from 60 mg to 30 mg; however, the US product label recommend no dosage adjustment. ††The US product label recommended dose reduction and use an initial dose of 80 mg followed by 40 mg once daily and monitoring considering blood loss. P-gp indicates P-glycoprotein; INF, interferon; IL, interleukin; TNF, tumor necrosis factor; INR, international normalized ratio; VTE, venous thromboembolism; AF, atrial fibrillation.
References

1. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):e438-e440.
2. Bowles L, Platton S, Yartey N, et al. Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. N Engl J Med. 2020;383(3):288-290. NEJMc2013656.
3. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-1026.
4. Morgan ET, Goralski KB, Miller MP, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos. 2008;36(2):205-216.
5. Liverpool COVID-19 Interactions. COVID-19 Drug Interactions. Revised 2020. Accessed August 8, 2020. https://www.covid19-druginteractions.org/checker/
6. Xarelto (rivaroxaban) [package insert]. Revised September 2019. Accessed August 8, 2020. https://www.bayer.ca/omr/online/xarelto-pm-en.pdf
7. Eliquis (apixaban) [package insert]. Revised November 2019. Accessed August 8, 2020. https://packageinserts.bms.com/pi/pi_eliquis.pdf
8. Lixiana (edoxaban) [package insert]. Revised February 2020. Accessed August 8, 2020. https://www.servier.ca/sites/default/files/webform/products/LIXIANA%20PMI%20%28clean%29-EN%20-%2012%20FEB%202020.pdf?ts=1585026046
9. Bevyxxa (rivaroxaban) [package insert]. Revised June 2017. Accessed August 8, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf
10. Garimella T, You X, Wang R, et al. A review of daclatasvir drug–drug interactions. Adv Ther. 2016;33(11):1867-1884.